Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Merck Manuals, a comprehensive digital health resource, announced today it has launched a new search tool enhanced by artificial intelligence to provide patients and other health care consumers with ...

Two new vaccine advisers tapped by Health and Human Services Secretary Robert F. Kennedy Jr. have served as paid expert ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...

Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the ...